Skip to main content

Table 1 Clinical characteristics of primary AML patient samples used for RNA sequencing

From: Blast cells surviving acute myeloid leukemia induction therapy are in cycle with a signature of FOXM1 activity

  Pre-chemotherapy Post-chemotherapy
BBa Age range Sex WHO (2016) WCC Karyotypeb Sample Inductionc Response Sample Blast %e Days since start of Rx Outcome
64 40–59 M AML with inv.(3) 14.1 Inv(3) PB ADE + GO Borderline refractory with persistent cytogenetic abnormality BM 5% 33 Relapsed and died following HSCTf
121 16–39 F AML with inv.(3) 6.5 Inv(3) BM DA + GO Refractory BM 30% 20 Transient remission with salvage therapy; then relapsed and died
205 40–59 F Therapy-related myeloid neoplasm (t-AML) 12.6 Monosomal PB DA (90)
FLAG-IDA4
Refractory BM 12% 62d Relapsed and died following HSCTf
285 60–79 M AML with myelodysplasia-related changes 3.9 Normal PB DA Refractory BM 30% 32 Induction failure; died
349 40–59 M AML, not otherwise specified 2.4 Normal BM DA Refractory BM 70% 38 Transient remission with salvage therapy; then relapsed and died
494 60–79 M AML, not otherwise specified 30.2 Monosomal BM DA Refractory BM 58% 32 Induction failure; died
  1. aBiobank identifier
  2. bSee Table 2 for details
  3. cInduction regimes: ADE Cytarabine, Daunorubicin, Etoposide; GO Gemtuzumab ozogamycin; DA Daunorubicin (standard dose 60 mg/m2, patient 205 received 90 mg/m2 as part of a clinical trial), Cytarabine; FLAG-IDA Fludarabine, Cytarabine, G-CSF, Idarubicin
  4. dThe post treatment sample for patient 205 was collected after a second cycle of chemotherapy. All other post-treatment samples were collected following induction chemotherapy
  5. eBlast percentage following treatment as determined by clinical service flow cytometry (FC). FC not performed for sample 64 2 M; results are shown for trephine histopathology (5%)
  6. fHSCT performed in the presence of persistent cytogenetic abnormality but morphological remission
  7. WCC, white cell count (× 109/l); PB, peripheral blood; BM, bone marrow; HSCT, hematopoietic stem cell transplantation; Rx, treatment